BioSpace News Archive

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, released the Annual Corporate Responsibility Report for 2020.

Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced that its investigational new drug ARDS-003 has been studied in a viral infected organoid model as part of a research collaboration between Targeted Pharmaceuticals and George Mason University.

Algenex SL and FATRO S.p.A announce that The Committee for Medical Products for Veterinary Use of the European Medicines Agency has recommended FATRO’S CrisBio®-based vaccine for Rabbit Haemorrhagic Disease for marketing authorization in the European Union.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced a Product Theater presentation at the upcoming 81st Scientific Sessions of the annual 2021 American Diabetes Association meeting taking place virtually June 25-29.

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, announced enrollment of the first subject in the OLYMPIA Phase 2 clinical trial of OC-01 nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy.

IBI-Ag, a biotechnology company developing a new class of bioinsecticides, announced an investment round for the optimization of its first product and expansion of the product portfolio spectrum.

Allogene Overland Biopharm, a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc., announced the appointment of Shuyuan Yao, Ph.D. as Chief Executive Officer.

XOMA Corporation today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock:

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced final, confirmatory results from the Phase 3 COMET-ICE trial demonstrating that sotrovimab, an investigational SARS-CoV-2 monoclonal antibody, significantly reduced the risk of hospitalization or death among high-risk adult outpatients with mild-to-moderate COVID-19.

Arcadia (arcadia.io), the leading population health management and health intelligence platform, today announced that it has been cited by KLAS Research as one of today’s most well-rounded population health management (PHM) vendors,4 standing out in terms of customer experience, market energy, and breadth of PHM capabilities